Treatment
Cell clinical trials
We’re tracking 5,682 recruiting studies that include Cell, each written for real people, not researchers, below.
Recruiting studies
- NCT07166757RecruitingPhase 1/Phase 2
Study of XS411 for early-onset Parkinson's disease
This trial tests a new treatment called XS411 for people with early-onset Parkinson's disease (age 50 or younger at diagnosis). It is for those whose motor symptoms are not well controlled with standard medications and who may benefit from a neurosurgical procedure.
Shanghai, Shanghai MunicipalityAges 18–70 - NCT07167329RecruitingPhase 2
Belzutifan for VHL syndrome: a real-world study
This trial tests the drug belzutifan (a pill taken by mouth) in people with VHL syndrome who have kidney or other VHL-related tumors that are growing or can be measured. The study looks at how well belzutifan works in real-world conditions and whether certain genetic factors affect how the drug works.
São Paulo, São PauloAges 14 years+ - NCT07170995RecruitingPhase 3
Study of SHR-8068 with adebrelimab and chemo for lung cancer
This trial tests a new combination of drugs (SHR-8068 plus adebrelimab and chemotherapy) against another approved combination for people with advanced non-small cell lung cancer who have not had treatment yet. The goal is to see which combination works better.
Jinan, ShandongAges 18–75 - NCT07172802RecruitingPhase 1/Phase 2
Study of GI-108 for advanced solid tumors
This trial tests a new drug called GI-108, which is designed to help your immune system fight cancer. It is for people with advanced or metastatic solid tumors that have not responded to other treatments.
SeoulAges 18 years+ - NCT07174388Recruiting
Study comparing treatments for advanced lung cancer using medical records
This trial does not test a new drug. It looks at existing medical records to compare how well different treatments work for people with advanced non-small cell lung cancer. You may be eligible if your cancer is advanced and you are not in another clinical trial.
Monterey, CaliforniaAges 18 years+ - NCT07174908RecruitingPhase 3
New drug combo vs standard therapy for KRAS G12C lung cancer
This trial tests two new targeted drugs (IN10018 and D-1553) together as a first treatment for advanced non-squamous lung cancer with a specific KRAS G12C mutation. It compares this combination to standard therapy to see if it works better.
Beijing, Beijing MunicipalityAges 18–80 - NCT07175051RecruitingPhase 2
Testing a kidney-protecting drug in sickle cell disease
This study tests whether empagliflozin, a medicine that protects the kidneys in people with diabetes, can also protect the kidneys in people with sickle cell disease. The goal is to see if it can reduce protein in the urine, which is a sign of kidney stress.
Chicago, IllinoisAges 18–60 - NCT07175077Recruiting
7T MRI scan to find tiny brain metastases in small-cell lung cancer
This trial uses a powerful 7T MRI scanner to detect very small brain metastases in people with small-cell lung cancer who choose not to get preventive brain radiation. The goal is to see if this advanced scan can find hidden spots in the brain that regular MRIs miss.
Columbia, MissouriAges 18 years+ - NCT07175220RecruitingPhase 2
Study of SHR2554 tablets combined with other treatments for lung cancer
This trial tests a new drug combination for people with non-small cell lung cancer that has spread or cannot be removed by surgery. It aims to see if adding SHR2554 tablets to other anticancer treatments can help control the disease.
Guangzhou, GuangdongAges 18–75 - NCT07175480RecruitingPhase 2
Stopping treatment for kidney cancer based on PET/CT results
This trial tests if people with advanced kidney cancer can safely stop all treatment if a special scan (PET/CT) shows their cancer has shrunk or disappeared. It's for those who have already been on a first-line immunotherapy plus targeted therapy for at least 12 months.
Nanjing, JiangsuAges 18 years+ - NCT07180992Recruiting
Monocytes and CART cell response in multiple myeloma
This trial looks at how certain immune cells (monocytes) affect the success of CART cell therapy for multiple myeloma. It may help doctors improve treatment for future patients.
AmiensAges 18 years+ - NCT07181720RecruitingPhase 1
CD70-targeted CAR-T therapy for advanced solid tumors
This trial tests a new treatment called CAR-T that targets a protein called CD70 on cancer cells. It is for people with advanced solid tumors that have not responded to or cannot tolerate standard treatments.
Hefei, AnhuiAges 18 years+ - NCT07182240Recruiting
Study of a new imaging method for skin cancer surgery
This study is testing a new imaging technology that helps surgeons see if all the cancer cells have been removed during Mohs surgery for basal cell carcinoma. It may help improve accuracy and reduce the need for additional surgeries.
Buffalo, New YorkAges 18 years+ - NCT07182682RecruitingPhase 3
Sunvozertinib after surgery for early-stage NSCLC with certain EGFR mutations
This trial tests the drug sunvozertinib given after surgery to see if it prevents lung cancer from coming back. It is for people with early-stage non-small cell lung cancer that has specific changes in the EGFR gene (exon20 insertion or PACC mutations).
BeijingAges 18 years+ - NCT07183384RecruitingPhase 1/Phase 2
Exosome therapy for blood vessel health after preeclampsia
This study tests whether exosomes from mesenchymal stem cells can help repair the blood vessels after preeclampsia. If you delivered within the last two weeks and had preeclampsia, you may qualify to take part.
Bandung, West JavaAges 18–50 - NCT07187713RecruitingPhase 4
Study of ACE Reno, Pico Cell Matrix for kidney health
This trial tests a new treatment called ACE Reno, Pico Cell Matrix to see if it can improve kidney function in people with chronic kidney disease (CKD) at various stages. It may be an option if you have early to moderate kidney issues (including after a transplant) and are already on standard therapies.
Giza, GZAges 18–80 - NCT07187882Recruiting
Skin cell transplant for vitiligo treatment
This trial tests a surgery that uses your own skin cells to treat stable vitiligo patches. It may help when creams or light therapy haven't worked.
Beijing, Beijing MunicipalityAges 8–65 - NCT07188077Recruiting
Study of immune changes in brain lymphoma
This trial looks at the immune system and metabolism of people with primary central nervous system lymphoma (a type of brain cancer) to find differences that might help with future treatments. It does not test a new drug, but collects samples and medical information.
Fuzhou, FujianAges 18–75 - NCT07188103RecruitingPhase 2
Ivonescimab and short radiation for advanced esophageal cancer
This trial combines a targeted immunotherapy drug (ivonescimab) with a short course of radiation to treat advanced esophageal cancer that has worsened after first treatment. It aims to see if this combination can help when standard options have stopped working.
Hefei, AnhuiAges 18–80 - NCT07189065RecruitingPhase 2
Rocbrutinib for relapsed or refractory non-GCB DLBCL
This trial tests a new targeted therapy, Rocbrutinib, for a specific type of aggressive B-cell lymphoma (non-GCB DLBCL) that has not responded to or returned after two or more prior treatments. It aims to see if Rocbrutinib can help people who have few other options.
Hefei, AnhuiAges 18 years+ - NCT07189455RecruitingPhase 3
Comparing ZG006 to chemotherapy for relapsed small cell lung cancer
This study compares a new drug called ZG006 against standard chemotherapy for people with small cell lung cancer that has come back after prior treatment. The goal is to see if ZG006 works better or has fewer side effects.
Shanghai, Shanghai MunicipalityAges 18–75 - NCT07190755Recruiting
Symptom tracking with a smartphone app for head and neck cancer
This trial uses a smartphone app to track your symptoms during radiation treatment for head and neck cancer. It aims to help your care team catch problems early and improve your quality of life.
RouenAges 18–75 - NCT07191847RecruitingPhase 4
Stem cell eye drops for dry eye disease
This trial tests whether stem cell fortified eye drops can improve tear film stability, tear volume, and dry eye symptoms. If you have dry eye disease and haven't had eye surgery or certain other eye conditions, you may be able to join.
GizaAges 18–80 - NCT07193667Recruiting
CAR-T therapy for autoimmune diseases
This study tests a type of immunotherapy called CAR-T for people with certain autoimmune diseases that have not responded to standard treatments. It aims to see if this cell therapy can calm the overactive immune system.
Shenyang, LiaoningAges 18–65
Common questions
- Are there clinical trials studying Cell?
- Yes. Clin2 currently lists 5,682 recruiting studies that include Cell, drawn from the U.S. registry and rewritten for real people so you can see what each is testing and who it's for.
- How do I know if I qualify for a Cell trial?
- Each study lists its own eligibility criteria — rules about condition, age, and prior treatments. On every Clin2 trial page we explain these in plain language and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Is Cell an approved treatment?
- A drug being studied in a trial may be investigational (still being tested) or already approved and being studied for a new use. Each study page explains what phase it's in. Clin2 does not provide medical advice — talk with your doctor about whether Cell or a specific trial is right for you.
Related treatments
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. A drug appearing here is being studied in a trial and may be investigational. Talk with your doctor about whether a specific treatment or trial is right for you.